Dr. Earle Burgess on appropriate patients for PARP inhibitors in mCRPC

“We showed that genetic correction of PSA levels has the potential to both reduce unnecessary biopsies and improve our ability to detect tumors with a more aggressive profile," says Linda Kachuri, PhD, MPH.

Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.

The phase 3 PROpel trial provided the primary supporting data for the approval.

“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.

Increasing numbers of older patients with cancer necessitates adoption of an age-friendly approach to cancer care.

“These results validate the clinical value of bone biomarker assessment in the HSPC state," state the authors.